# Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type

> **NCT02168920** · PHASE3 · TERMINATED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 150 (actual)

## Conditions studied

- Agitation Associated With Dementia of the Alzheimer's Type

## Interventions

- **DRUG:** 2 mg/day
- **DRUG:** 3 mg/day
- **DRUG:** 6 mg/day
- **DRUG:** Placebo (0 mg/day)

## Key facts

- **NCT ID:** NCT02168920
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-06-11
- **Primary completion:** 2016-03-18
- **Final completion:** 2016-03-18
- **Target enrollment:** 150 (ACTUAL)
- **Why stopped:** It was difficult to secure enrollment of the targeted number of subjects.
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02168920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02168920, "Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02168920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*